Implantable cardioverter-defibrillator (ICD) – Related resources
03.06.2016 • Sonuncu dəyişiklik 16.06.2009
This article is created and updated by the EBMG Editorial Team
Other Evidence summaries
- Adjunctive antiarrhytmic drug therapy in patients with implantable cardioverter defibrillators (ICD) may reduce ICD shock therapies. The magnitude of the benefit seems to be higher with amiodarone but its use is associated with potential safety concerns .
Literature
- Epstein AE, DiMarco JP, Ellenbogen KA et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices), American Association for Thoracic Surgery, Society of Thoracic Surgeons. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task
Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 2008 May 27;51(21):e1-62.
- Myerburg RJ. Implantable cardioverter-defibrillators after myocardial infarction. N Engl J Med 2008 Nov 20;359(21):2245-53.